High Value Proteins
The Company has promising laboratory results in hand for our first mid-term target, the expression of therapeutic proteins in algae. The company has used its proprietary technology to produce the highest published amounts of therapeutic proteins from algae, and is using this technology to produce Bone Morphogenetic Protein (BMP). BMP is applied during orthopedic surgery to fractures to accelerate bone growth and speed recovery. Solarvest BioEnergy Inc. believes that production in algae will supply a highly bioactive product, and will substantially reduce the cost of manufacture, allowing the company to sell this algae-derived therapeutic at a substantially reduced cost. Algae have the ability to produce complex proteins that are highly effective since they have the appropriate cell biological processes/cell machinery to produce biomolecules that are closer to natural active forms – biologically and three-dimensionally similar.
The Company envisions direct sales to the veterinary market with bulk active protein sold to multinational pharmaceutical companies for the human distribution channel. The currently active human pharmaceutical supplier sells one billion globally (company presentation data) but market penetration has been limited due to the extreme cost. This low volume high value human market is currently supplied by one company so it is an ideal first product for Solarvest.